H.C. Wainwright raised the firm’s price target on Krystal Biotech (KRYS) to $310 from $240 and keeps a Buy rating on the shares. The KB407 clinical update delivered positive molecular proof-of-concept in cystic fibrosis patients, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Early Proof-of-Concept and Platform Potential Drive Buy Rating on Krystal Biotech Despite Pending Lung Function Data
- Krystal Biotech advances KB407 with positive CF trial data
- Krystal Biotech announces interim update from highest dose cohort of CORAL-1
- Krystal Biotech price target raised to $272 from $255 at BofA
- Krystal Biotech upgraded to Buy from Neutral at Citi